Rheumatoid Arthritis News

Among patients with rheumatoid arthritis, smoking history is not associated with the presence of anti-peptidylarginine deiminase 4 antibodies, which have been linked to more severe disease activity, according to findings published in Arthritis Research and Therapy.

Certolizumab pegol for chronic inflammatory disease does not pose a teratogenic risk for pregnant women, nor does it increase the risk for fetal death, according to findings published in Arthritis & Rheumatology.

Temporarily ceasing methotrexate for 2 weeks following seasonal influenza vaccination improves the vaccine’s immunogenicity, without increasing rheumatoid arthritis disease activity, according to findings published in the Annals of the Rheumatic Diseases.

Among patients with rheumatoid arthritis who had previously been treated with methotrexate, the effectiveness and safety of tofacitinib was not demonstrably different than that of non-TNF biologics, according to findings published in Arthritis Research & Therapy.

Recently published findings revealed that women with rheumatoid arthritis and psoriasis have an increased risk for major adverse cardiac events compared with the general population.

The FDA has rejected approval of Celltrion’s biologics license applications for Truxima, a proposed rituximab biosimilar, and Herzuma, a proposed trastuzumab biosimilar, issuing Complete Response Letters for both products.

Samsung Bioepis and Abbvie have reached a global settlement agreement regarding the commercialization of SB5, the proposed adalimumab biosimilar for Humira, according to a press release.

Patients with arthritis who are younger, have rheumatoid factor positivity and demonstrate higher disease activity at baseline are at an increased risk for experiencing methotrexate failure due to inefficacy, according to findings published in Arthritis Care & Research.

Read the case of a woman who was diagnosed with rheumatoid arthritis 2 years prior. She improved on her initial treatment but after 1-year treatment had to be discontinued.

Although sirukumab monotherapy demonstrated greater improvements than adalimumab monotherapy among patients with rheumatoid arthritis when measured using erythrocyte sedimentation rate, the two treatments were generally similar in terms of participants who achieved the ACR50 response rate.